LEO Lymphoma study participants
The Lymphoma Epidemiology of Outcomes (LEO) Study follows up with existing participants and engages in targeted recruitment of new participants by invitation.
Eligibility and procedures
After providing informed consent, study participants complete questionnaires, give a one-time blood sample, allow review of diagnostic biopsy material, and permit study staff to review medical records.
People are eligible for the study if they have been diagnosed with lymphoma within six months of enrollment and are actively being seen by a hematology healthcare professional at a participating center, including:
- Mayo Clinic.
- Emory University or Grady Health System.
- MD Anderson Cancer Center.
- The University of Iowa.
- University of Miami or Jackson Memorial Hospital.
- University of Rochester Medical Center.
- Washington University in St. Louis.
- Weill Cornell Medical Center.
Frequently asked questions
How will the LEO study benefit me?
There's no direct benefit to individual participants in the LEO study. However, data from the study help researchers gain a better understanding of what factors might lead to longer and better survival and survivorship in people with non-Hodgkin lymphoma.
The LEO research team ultimately hopes to discover innovative methods to improve care and quality of life for people with lymphoma.
How long is the study?
Study researchers track each participant for their entire survivorship experience because we're interested in both short-term and long-term outcomes. Data analysis is ongoing. The study was extended and funded through March 2026.
How is confidentiality protected?
Only the LEO study personnel at Mayo Clinic know a participant's identity. Each study center can view only its own participants' information. Participant identity isn't shared with any researcher outside of the study. Information learned about participants through this study doesn't become part of their medical records.
Who can participate?
Participants must have been diagnosed within six months of enrollment to be eligible for participation in the LEO study, regardless of their treatment status.
Contact
For information about the Mayo Clinic LEO lymphoma study, contact Dr. Cerhan's team at 800-610-7093 (toll-free) or by email at lymphoma@mayo.edu.
Visit the LEO Cohort website for more information.
Visit ClinicalTrials.gov to learn more about the Lymphoma Epidemiology of Outcomes cohort study.